Skip to content
Peptigraph home

Tesamorelin vs Tirzepatide: What the Research Shows

Tesamorelin and Tirzepatide side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[16]Growth hormoneGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[17]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Tesamorelin if…

  • you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[7]
  • you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[16]

Consider Tirzepatide if…

  • you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[18]
  • you want large randomized weight-loss data (the SURMOUNT program): Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo.[17]
  • you are tested in sport and want to avoid a WADA-prohibited substance: WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin (check tirzepatide's own status separately)[4]
Tesamorelin is prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 10 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldTesamorelinTirzepatide
ClassGHRH analogGLP-1 / GIP dual agonist
Also calledtesa, Egriftatirz, tirze, Mounjaro, Zepbound
CategoryGrowth hormoneGLP-1 & metabolic
FDA statusFDA approved (Egrifta)FDA approved (Mounjaro, Zepbound)
WADAProhibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
None reportedanti-doping literature, as of 2 Oct 2026
Half-life11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Human studies we summarised12 human (11 randomized or controlled) of 16 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg, 20 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Tesamorelin and Tirzepatide together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Open the stack page

Visceral fat in HIV versus weight loss in obesity

The Egrifta WR label states that the drug has a weight neutral effect and is not indicated for weight loss management.[7]

In a tirzepatide trial, weight change was -20.9% with 15-mg doses against -3.1% with placebo.[17]

Tesamorelin lowered visceral fat in an HIV trial: 15.2% down on tesamorelin, 5.0% up on placebo.[16]

In obese subjects with relative reductions in GH, tesamorelin selectively reduced visceral fat without significant effects on subcutaneous adipose tissue.[19]

A meta-analysis of tesamorelin in HIV observed growth hormone-related adverse effects and higher discontinuation rates; the discontinuation difference did not reach statistical significance (p = 0.06).[20]

Schedule and labelled use

The Egrifta WR label's recommended dosage is 1.28 mg subcutaneously once daily.[7]

The Zepbound label says to increase the dosage in 2.5 mg increments after at least 4 weeks until the recommended maintenance dosage is achieved.[18]

The Zepbound label's indication is to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related comorbid condition.[18]

The tesamorelin label lists glucose intolerance or diabetes mellitus among conditions that may develop with Egrifta WR use.[7]

Tesamorelin is a named example in WADA's GHRH-analogue entry.[4]

Common questions

Is tesamorelin or tirzepatide better for belly fat?

Egrifta WR's label is explicit that it is not indicated for weight loss management.[7]

Can you take tesamorelin and tirzepatide together?

No study in the cached results combines them. The tesamorelin label says glucose intolerance or diabetes mellitus may develop with use.[7]

Tesamorelin vs Mounjaro: what is the difference?

Tesamorelin (Egrifta WR) is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.[7]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  6. 6Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  7. 7EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  8. 8The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  9. 9Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  10. 10The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  11. 11These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  12. 12Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  13. 13Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  14. 14Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  15. 15PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  17. 17Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  18. 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  19. 19Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
  20. 20Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026

Found an error? Report a correction.